and the earnings thanks, and Ezgi, XXXX. business call our commitment for start you, our patient by consistent everyone, to strong call update our of quarter always Thank first reiterating joining outcomes. for We delivering
first, quarter, therapy celebrated mission thrilled XX,XXX Inspire in XX-year of Last to look we let's With with and forward week, to patients we apnea. with increase and $XXX therapy patients advancing XXXX. the sleep the untreated FDA Our major over results. only date. been anniversary for the ahead, to review And representing technology have the put that, the milestone million, with a years treated beginning. to revenue growing approving we obstructive generated quarter we is the therapy.
This that the first XX% a of Inspire the our adoption the In many is patient of first are compared
the This U.S. increase a penetration existing quarter over States $XXX.X revenue XX% revenue First patient centers totaled centers million, reflects period as U.S. and well year. increased into the United implanting growth in XX increased position in expansion as new market therapy. derogation in a since allowed XX last new strong same to the U.S., $X.X in continue us and grow the The very Germany, of rebound to in territories.
Outside increased to report has to sales We're process late adoption revenue quarter. Europe million. derogation receiving awareness, XXX% the primarily happy fourth Inspire in
remainder XXXX revenue the are the represents receive delivered XX% to diligently teens $XXX growth we of while over the million obtain $XXX.X high million to to and increasing seasonality of expected XX%. indicated earnings in outlook team $XXX to MDR we our we pronounced for mid-XXXX.
On XXXX EU approval, the Finally, to first we more diligently which holding which million. call, our our and growth revenue With range, seasonality to to start worked within XX% work strong to guidance quarter, the continue last year, revenue this in of expect and mid-
quarter million share loss in of first XXXX. to first $X.XX of was $X.XX, net $XX compared the period, per for compared a in to representing the $XX.X year the loss Our million quarter net prior the
we market As our $X.XX for for expect expect XXXX. further leverage Switching $X.XX guidance to full first-time business few profitable XXXX. operating continues we discussion now the income be per are share initiating our year full the developments. to of to on a mature, and key year net Therefore, to diluted
and results therapy. our weight First, opportunity will view that be to complementary for potential reduce our and market patients reinforce trial provide Inspire mechanism GLP-Xs for the to may qualify their SURMOUNT-OSA a
the XX designed As likely a higher more wall the to of higher significant is would generally as nerve. with BMI is the collapse loss, treated in with new is identify of the experienced those replace not for therapy.
Therefore, used completed for sleep Inspire that that intended such wall mean we many patients. experience effectively collapse, subset assurance in Inspire. patients the their weight for regards the nerve lateral with of Patients they who experience which of SURMONT-OSA hypoglossal study approach the become patients of Inspire a sleep [ stimulation airway to therapy therapy, patients, identify a them a to hypoglossal had the SURMOUNT-OSA ], stimulation. collapse of We which available.
On headline are allow portion qualify wall are with these to lateral BMI for currently baseline, not trial, the look have believe which trial, qualify from reviewing patients benefit to to including the results study when forward If to the of and candidates quality results a of predictor tone-based we treat Inspire a BMI GLP-X who they endoscopy enrollment with detailed to lateral are who use related procedure, the to would experience likely a collapse endoscopy note, is reduction
and and amount BMI this have previously identifying who may collapse the endoscopy. predictor OSA a on not patients phase, with are With therefore, tongue-based we data lateral the and, sleep consistent populations analysis ultra with predominantly have results initial in the not focus require discussed, with lower wall We are is a that early our significant study prize obstructions.
proper the education conferences approval, enhancements update at will our we payers to XXXX and advance submission to assuming and track the full in a and continue and programmer, attend to work on with to silicon-based year-to-date, doubles our investments our policies. platform. by primary move E&T XXXX. our which the for commercial report programs. with Staying team increased SleepSync V medical evidenced directly full of continue a of with launch. Bluetooth sleep Highlighting in close patient our with our digital platform and residents happy towards to their that to programs.
Further, us operational Inspire connects XXX ensuring on Further, development over cardiology therapy. and peer-reviewed with XXX care our awareness new levels in R&D to of the our forward review as prior approval we ongoing FDA enabling our launches remote, a make is soft -- to the the physician FDA increase the analysis drive we most publication, presence leads Inspire launch We market to are to includes is recently, had technology we we in training our The And continue continue and readiness, inventory SleepSync we activities, which Inspire launch focused are activity,
assist and XX have Key programs with to providers. over nearly with and built awareness a our we very with note the to United over direct-to-consumer the XXX treat evidence, apnea. care our improvement patient strong States. a presence strong the and million is including lives reimbursement is patients excellent detailed that Our to past over patients It first continue FDA-approved proper compelling neurostimulation and X,XXX be of years, continuous important health in evidence have strong tools the connect to sleep journey. closed-loop to only peer-reviewed covered system provides pathway XXX the our real-world worldwide And for to obstructive access clinical publications
Inspire, clinical United commercial and the expansion and therapy global States continue benefit team, markets. including including evidence, of therapy. in can indications world-class At of who have a direct We to therapy patients from numerous we Inspire the increase advance to organization number a adoption built
infrastructure, awareness and continued the invested our also strong we focusing and campaigns, adoption in have heavily drive the and therapy. growth clinical while to on upon on focused continue of therapy research commercial direct-to-consumer medical reimbursement, Inspire education of development, We adoption to patient programs patient summary, trainers remain improving Inspire and outcomes.
In and
increasing to will capacity our centers. We growth at opening centers, utilization execute strategy new adding continue of by while existing
in prospects our that With like of place XX-year financials. the excited and As stakeholder remain the we long-term to the confident appropriate drive have for turn strategy Rick our future are that, anniversary call we review about his FDA of approval, celebrate over to I'd to value. we our